The terrible events of 2023 were born of a decade-old policy failure

March 11, 2025 Latest News BioPharma Comment

This is a preview of subscriber content

Subscribe now to continue reading.

Biosimilar policy is the perfect example of what happens when the industry does not deliver constructively, with the government forced into policy responses like the disastrous 2023 catch-up statutory price reductions. …

Subscribe now to continue reading.

Latest Video

Health Department clarifies PBAC plan after confusion over paediatric access to biologics
December 10, 2025 - Latest News
If this was the plan, why wasn't it included in the response to questions last week?
December 10, 2025 - Latest News
Immutep strikes major licensing deal with Dr. Reddy’s to commercialise novel cancer immunotherapy
December 9, 2025 - Australian Biotech
Pfizer’s high-stakes sprint to build momentum in century-defining market
December 11, 2025 - Latest News
Mayne Pharma rejects Cosette’s attempt to terminate scheme deal
December 10, 2025 - Latest News

The terrible events of 2023 were born of a decade-old policy failure

This is a preview of subscriber content

Latest Video

Most Read

Health Department clarifies PBAC plan after confusion over paediatric access to biologics

If this was the plan, why wasn't it included in the response to questions last week?

Immutep strikes major licensing deal with Dr. Reddy’s to commercialise novel cancer immunotherapy

Pfizer’s high-stakes sprint to build momentum in century-defining market

Mayne Pharma rejects Cosette’s attempt to terminate scheme deal

New Stories

Medicines Australia gains a new voice with Vertex joining the association

BMS marks 70 years in Australia with renewed commitment to innovation and access

Opportunity cost is a moral and ethical question when it involves travel, tickets, or treating sick children

Pfizer’s high-stakes sprint to build momentum in century-defining market

Mayne Pharma rejects Cosette’s attempt to terminate scheme deal

TGA clears the way for LTR Pharma’s Phase 2 Study of SPONTAN

OncoSil announces first UK patient treated with its pancreatic cancer treatment

Sign In

The terrible events of 2023 were born of a decade-old policy failure

This is a preview of subscriber content

Latest Video

Most Read

Health Department clarifies PBAC plan after confusion over paediatric access to biologics

If this was the plan, why wasn't it included in the response to questions last week?

Immutep strikes major licensing deal with Dr. Reddy’s to commercialise novel cancer immunotherapy

Pfizer’s high-stakes sprint to build momentum in century-defining market

Mayne Pharma rejects Cosette’s attempt to terminate scheme deal

Follow Us

New Stories

Medicines Australia gains a new voice with Vertex joining the association

BMS marks 70 years in Australia with renewed commitment to innovation and access

Opportunity cost is a moral and ethical question when it involves travel, tickets, or treating sick children

Pfizer’s high-stakes sprint to build momentum in century-defining market

Mayne Pharma rejects Cosette’s attempt to terminate scheme deal

TGA clears the way for LTR Pharma’s Phase 2 Study of SPONTAN

OncoSil announces first UK patient treated with its pancreatic cancer treatment